# Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old

> **NCT05015686** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Sinovac (Dalian) Vaccine Technology Co., Ltd.** · enrollment: 2400 (estimated)

## Conditions studied

- Varicella

## Interventions

- **BIOLOGICAL:** Live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd
- **BIOLOGICAL:** Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd
- **BIOLOGICAL:** Live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05015686
- **Lead sponsor:** Sinovac (Dalian) Vaccine Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2021-09-30
- **Primary completion:** 2022-02-09
- **Final completion:** 2026-09-20
- **Target enrollment:** 2400 (ESTIMATED)
- **Last updated:** 2024-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05015686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05015686, "Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05015686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*